Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma.
Cancer Res
; 79(21): 5612-5625, 2019 Nov 01.
Article
in En
| MEDLINE
| ID: mdl-31492820
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Adenocarcinoma
/
Proto-Oncogene Proteins p21(ras)
/
Carcinoma, Pancreatic Ductal
/
Decitabine
Type of study:
Prognostic_studies
/
Risk_factors_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Cancer Res
Year:
2019
Document type:
Article